Epsilon Healthcare achieved record customer receipts of A$2.9 million in the December quarter, a 96% increase on the same period the prior year, as the company's recovery continued to gain traction.
Across the full 12 months to 31 December 2025, receipts reached $9.2m, representing a 71% rise compared to 2024.
The result capped a positive stretch for the company, which was reinstated to the Australian Securities Exchange (ASX) in December after a two-year trading suspension that followed its entry into voluntary administration at the close of 2023.
Epsilon emerged from voluntary administration through a deed of company arrangement (DOCA) in June 2025 — a development that set off a renewed upturn in operational activity.
Managing director Peter Giannopoulos cited monthly group revenue — which has been consistently surpassing $1m — as a sign that the company's recovery remained on track.
"The December quarter marked a clear inflection point for Epsilon," Giannopoulos said. "Epsilon enters 2026 with increasing operating leverage and a clear pathway to sustainable profitability.
"Our focus is firmly on scaling the business, disciplined capital allocation, and translating this momentum into long-term shareholder value."
The company reported growth across every division, including Epsilon Pharma's onshore GMP manufacturing arm, Epsilon Clinics, and the newly launched Epsilon Pharmacy.
Cash on hand at quarter's end was $242,000, down from $643,000 the previous quarter, with the decline attributed to debt repayments.
Total available funding stood at $2.2m, which the company said equated to an estimated 3.6 quarters of funding at current cash flow levels.
Giannopoulos said the company intended to build on its recent "operational momentum" throughout 2026.
